203-7D10
203-7D10
规格:
货期:
编号:TS212986
品牌:Testobio
| 产品名称： | 203-7D10 |
|---|---|
| 商品货号： | TS212986 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension but many cells attach |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Cancer |
| Applications： | Animals were immunized with a synthetic polypeptide with the sequence (C)GSSKSKPKDPSQRRHS corresponding to peptides 2 to 17 of the v-src oncogene. In immunoblot screening, the antibody detects a 60 kd protein in the src transformed T2 cell line. A number of additional proteins are also detected in cell lines and embryo tissues including a 50 kd protein in the urine of cancer patients as well as the amniotic fluid of pregnant patients. |
| Derivation： | Spleen cells were fused with Sp2/0 myeloma cells. |
| Clinical Data： | A number of additional proteins are also detected in cell lines and embryo tissues including a 50 kd protein in the urine of cancer patients as well as the amniotic fluid of pregnant patients. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against a synthetic v-src oncogene peptide |
| Cellular Products： | immunoglobulin; monoclonal antibody; against a synthetic v-src oncogene peptide |
| Comments： | Animals were immunized with a synthetic polypeptide with the sequence (C)GSSKSKPKDPSQRRHS corresponding to peptides 2 to 17 of the v-src oncogene. Spleen cells were fused with Sp2/0 myeloma cells. In immunoblot screening, the antibody detects a 60 kd protein in the src transformed T2 cell line. A number of additional proteins are also detected in cell lines and embryo tissues including a 50 kd protein in the urine of cancer patients as well as the amniotic fluid of pregnant patients. The reactivity of the antibody with the src peptide (2-17) was confirmed by ELISA. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml. Maintain cell density between 2 X 10 exp5 and 2 X 10 exp6 viable cells/ml. |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG2a; IgG2b |
| Name of Depositor： | National Cancer Institute |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| References： | Niman HL, Lerner RA. Polypeptide-induced monoclonal receptors to protein ligands. US Patent 5,015,571 dated May 14 1991 |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
203-7D10
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | 203-7D10 |
|---|---|
| 商品货号： | TS212986 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension but many cells attach |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Cancer |
| Applications： | Animals were immunized with a synthetic polypeptide with the sequence (C)GSSKSKPKDPSQRRHS corresponding to peptides 2 to 17 of the v-src oncogene. In immunoblot screening, the antibody detects a 60 kd protein in the src transformed T2 cell line. A number of additional proteins are also detected in cell lines and embryo tissues including a 50 kd protein in the urine of cancer patients as well as the amniotic fluid of pregnant patients. |
| Derivation： | Spleen cells were fused with Sp2/0 myeloma cells. |
| Clinical Data： | A number of additional proteins are also detected in cell lines and embryo tissues including a 50 kd protein in the urine of cancer patients as well as the amniotic fluid of pregnant patients. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against a synthetic v-src oncogene peptide |
| Cellular Products： | immunoglobulin; monoclonal antibody; against a synthetic v-src oncogene peptide |
| Comments： | Animals were immunized with a synthetic polypeptide with the sequence (C)GSSKSKPKDPSQRRHS corresponding to peptides 2 to 17 of the v-src oncogene. Spleen cells were fused with Sp2/0 myeloma cells. In immunoblot screening, the antibody detects a 60 kd protein in the src transformed T2 cell line. A number of additional proteins are also detected in cell lines and embryo tissues including a 50 kd protein in the urine of cancer patients as well as the amniotic fluid of pregnant patients. The reactivity of the antibody with the src peptide (2-17) was confirmed by ELISA. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml. Maintain cell density between 2 X 10 exp5 and 2 X 10 exp6 viable cells/ml. |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| Isotype： | IgG2a; IgG2b |
| Name of Depositor： | National Cancer Institute |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| References： | Niman HL, Lerner RA. Polypeptide-induced monoclonal receptors to protein ligands. US Patent 5,015,571 dated May 14 1991 |
